Aimee DeGolyer was named the winner of Astellas Pharma U.S.’s sixth annual C3 (Changing Cancer Care) Prize, a global challenge that funds the best non-treatment ideas to improve cancer care for patients, caregivers, and the broader oncology community.
The European Medicines Agency’s Committee for Medicinal Products for Human Use adopted a positive opinion recommending approval of Keytruda in combination with Padcev (enfortumab vedotin-ejfv), an antibody-drug conjugate, for the first-line treatment of adult patients with unresectable or metastatic urothelial carcinoma.
